Welcome to our dedicated page for Amicus Therapeut SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amicus Therapeutics, Inc. (NASDAQ: FOLD) SEC filings page on Stock Titan provides access to the company’s official disclosures as a rare disease biotechnology issuer. Amicus describes itself as a global, patient-dedicated biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases, including Fabry disease and late-onset Pompe disease.
Key filings for FOLD include current reports on Form 8-K that summarize material events and financial updates. For example, Amicus has filed 8-K reports to furnish press releases announcing quarterly financial results for periods ended June 30, 2025 and September 30, 2025. These filings identify the company’s common stock as listed on NASDAQ under the symbol FOLD and outline that the information provided under Item 2.02 (Results of Operations and Financial Condition) is furnished rather than filed for certain liability purposes.
Through its periodic reports and exhibits, Amicus details net product revenues for Galafold (migalastat) and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), operating expenses, non-GAAP measures and cash position. These documents also describe the company’s focus on rare disease medicines and provide context for its commercial performance and research investments.
Investors can also expect SEC filings related to significant corporate transactions. On December 19, 2025, Amicus and BioMarin Pharmaceutical Inc. announced a definitive agreement for BioMarin to acquire Amicus in an all-cash transaction, a development that would typically be reflected in transaction-related filings and proxy materials as the process advances, subject to regulatory and stockholder approvals.
On Stock Titan, Amicus filings are supplemented by AI-powered tools that help explain the content and structure of documents such as 8-Ks, quarterly reports and, when available, annual reports and proxy statements. Users can review real-time updates from EDGAR, track how Amicus reports on its rare disease portfolio and commercial performance, and examine the regulatory record that underpins analysis of FOLD as a biotechnology stock.
Amicus Therapeutics, Inc. notified Nasdaq of the removal of its Common Stock from listing and registration on the Nasdaq Stock Market. The filing states the Exchange "struck the class of securities from listing" and that the issuer complied with rules "governing the voluntary withdrawal".
Amicus Therapeutics, Inc. reports that the French Ministry of Economics and Finance granted clearance on April 23, 2026 for its planned merger with BioMarin Pharmaceutical under French foreign direct investment screening rules. This clearance satisfies the final outstanding regulatory condition to the merger, aside from items customarily completed at closing.
The merger, under which Amicus will become a wholly owned subsidiary of BioMarin, is now expected to close on April 27, 2026, subject to those remaining closing conditions. The company also reiterates that statements about the expected timing of completion are forward-looking and subject to various risks and uncertainties.
The Vanguard Group amended its Schedule 13G/A to report 0% beneficial ownership of Amicus Therapeutics Inc common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The Schedule 13G/A records Amount beneficially owned: 0 and Percent of class: 0%, with the amendment signed on 03/26/2026.
Amicus Therapeutics President and CEO Bradley L. Campbell sold 22,500 shares of common stock in an open-market transaction. The sale took place at a weighted average price of $14.3484 per share on March 2, 2026, with individual trade prices ranging from $14.34 to $14.37. After this transaction, he continues to hold 998,680 shares of Amicus Therapeutics common stock directly.
Amicus Therapeutics reported that its stockholders approved the company’s pending acquisition by BioMarin Pharmaceutical at a special meeting held on March 3, 2026. As of the January 28, 2026 record date, 313,918,463 shares of Amicus common stock were eligible to vote, and 234,785,243 shares, or about 74.79% of outstanding shares, were represented in person or by proxy.
Stockholders adopted the Agreement and Plan of Merger between Amicus, BioMarin and Lynx Merger Sub 1, Inc., with 234,593,492 votes for, 119,194 against and 72,557 abstentions. They also approved, on a non-binding advisory basis, certain merger-related compensation for named executive officers, with 209,150,012 votes for, 24,282,220 against and 1,353,011 abstentions.
The approval of the merger proposal satisfies the stockholder approval condition in the merger agreement. The companies noted that the U.S. Federal Trade Commission had already granted early termination of the Hart-Scott-Rodino waiting period on February 11, 2026. Completion of the transaction remains subject to other customary closing conditions, including regulatory clearances in specified non-U.S. jurisdictions, and is expected to close in the second quarter of 2026.